

# UC San Diego

## UC San Diego Previously Published Works

### Title

Implementation of SARS-CoV-2 Monoclonal Antibody Infusion Sites at Three Medical Centers in the United States: Strengths and Challenges Assessment to Inform COVID-19 Pandemic and Future Public Health Emergency Use

### Permalink

<https://escholarship.org/uc/item/1z55r2tz>

### Authors

Lambrou, Anastasia S  
Redd, John T  
Stewart, Miles A  
et al.

### Publication Date

2023

### DOI

10.1017/dmp.2022.15

Peer reviewed

## Concepts in Disaster Medicine

**Cite this article:** Lambrou AS, Redd JT, Stewart MA, et al. Implementation of SARS-CoV-2 monoclonal antibody infusion sites at three medical centers in the United States: strengths and challenges assessment to inform COVID-19 pandemic and future public health emergency use. *Disaster Med Public Health Prep.* doi: <https://doi.org/10.1017/dmp.2022.15>.


### Keywords:

COVID-19 pandemic; infusion; medical countermeasure; monoclonal antibody; pandemic response

### Corresponding author:

John T. Redd,  
Email [john.redd@hhs.gov](mailto:john.redd@hhs.gov).

# Implementation of SARS-CoV-2 Monoclonal Antibody Infusion Sites at Three Medical Centers in the United States: Strengths and Challenges Assessment to Inform COVID-19 Pandemic and Future Public Health Emergency Use

Anastasia S. Lambrou<sup>1,2</sup> , John T. Redd<sup>1</sup>, Miles A. Stewart<sup>1,2</sup>, Kaitlin Rainwater-Lovett<sup>1,2</sup>, Jonathan K. Thornhill<sup>1,2</sup>, Lynn Hayes<sup>1</sup>, Gina Smith<sup>1</sup>, George M. Thorp<sup>1</sup>, Christian Tomaszewski<sup>3,4</sup>, Adolphe Edward<sup>3,4</sup>, Natalia Elías Calles<sup>5</sup>, Mark Amox<sup>6</sup>, Steven Merta<sup>6</sup>, Tiffany Pfundt<sup>1</sup>, Victoria Callahan<sup>1</sup>, Adam Tewell<sup>1</sup>, Helga Scharf-Bell<sup>1</sup>, Samuel Imbriale<sup>1</sup>, Jeffrey D. Freeman<sup>1,2</sup>, Michael Anderson<sup>1</sup> and Robert P. Kadlec<sup>1</sup>

<sup>1</sup>Office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services, Washington, DC, USA; <sup>2</sup>Johns Hopkins University Applied Physics Laboratory, Laurel, MD, USA; <sup>3</sup>El Centro Regional Medical Center, El Centro, CA, USA; <sup>4</sup>UC San Diego Health, San Diego, CA, USA; <sup>5</sup>TMC HealthCare, Tucson, AZ, USA and <sup>6</sup>Sunrise Hospital and Medical Center, Las Vegas, NV, USA

## Abstract

Monoclonal antibody therapeutics to treat coronavirus disease (COVID-19) have been authorized by the US Food and Drug Administration under Emergency Use Authorization (EUA). Many barriers exist when deploying a novel therapeutic during an ongoing pandemic, and it is critical to assess the needs of incorporating monoclonal antibody infusions into pandemic response activities. We examined the monoclonal antibody infusion site process during the COVID-19 pandemic and conducted a descriptive analysis using data from 3 sites at medical centers in the United States supported by the National Disaster Medical System. Monoclonal antibody implementation success factors included engagement with local medical providers, therapy batch preparation, placing the infusion center in proximity to emergency services, and creating procedures resilient to EUA changes. Infusion process challenges included confirming patient severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity, strained staff, scheduling, and pharmacy coordination. Infusion sites are effective when integrated into pre-existing pandemic response ecosystems and can be implemented with limited staff and physical resources.

## Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and ignited a global pandemic with detrimental impacts on health systems across the world. This novel virus caught the globe unprepared without targeted medical countermeasures (MCMs), such as therapeutics, to treat individuals with coronavirus disease (COVID-19). As the pandemic progressed and scientific progress was rapidly stimulated, the therapeutic toolkit to treat COVID-19 evolved to include monoclonal antibodies.<sup>1</sup> Monoclonal antibody therapeutics to treat COVID-19 are composed of laboratory-synthesized SARS-CoV-2 neutralizing antibodies, most often isolates from infected individuals, and isolated for specific immunologic properties such as binding, neutralization, and effector functions.<sup>2</sup> Multiple formulations and forms of administration of monoclonal antibodies have been authorized by US Food and Drug Administration's under Emergency Use Authorization (EUA) for both post-exposure prophylaxis and treatment.<sup>3</sup> Recent clinical trials on monoclonal antibody therapies suggest that early use of these drugs can reduce COVID-19 symptom severity, SARS-CoV-2 viral load, and hospitalization in infused outpatient populations as compared to individuals given placebos.<sup>4-6</sup> Real-world effectiveness studies have also provided evidence that monoclonal antibody infusions reduce hospitalization rates in high-risk patient populations.<sup>7-9</sup> These monoclonal antibody therapies are currently administered as intravenous infusions to treat individuals with mild to moderate COVID-19. The EUAs also specify monoclonal antibody infusion eligibility requirements for potential patients at high risk for COVID-19 complications, such as age, Body mass index, and pre-existing conditions (SI Table 1). EUAs are regulatory tools used

© The US Department of Health and Human Services and The Author(s), 2022. This is a work of the US Government and is not subject to copyright protection within the United States. Published by Cambridge University Press on behalf of Society for Disaster Medicine and Public Health, Inc. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.

during public health emergencies, such as pandemics, to expand use, system implementation, and further study of new therapeutics.<sup>10</sup>

Despite the EUAs and promising clinical trial results, monoclonal antibody therapies are currently underutilized as a treatment for COVID-19 across the United States. This is hypothesized to be due to gaps in outreach to both providers and patient communities, strict EUA criteria, and infusion site implementation barriers during the ongoing pandemic, such as staffing, resources, and infection control.<sup>11</sup> Incorporating monoclonal antibodies into COVID-19 response efforts may relieve stress on medical centers through reducing disease severity and hospitalizations.<sup>12</sup> Monoclonal antibody use is increasing in some settings across the United States, but there is limited research on the implementation of this therapy, resources needed to maintain an infusion site, and lessons learned to inform the scale-up of this pandemic response tool. Monoclonal antibody therapeutics may also play a critical role in future emerging biological threats, including the newly described, emerging variant SARS-CoV-2 isolates, as they can be rapidly manufactured and can be used as a treatment before other MCMs, such as vaccines, evaluated, and distributed.<sup>13</sup> Vaccines may also require multiple weeks or doses to elicit protection, while monoclonal antibodies serve as a treatment to reduce the burden of a novel pathogen. It is critical to learn from the ongoing implementation of monoclonal antibody infusions during the COVID-19 pandemic to inform the scale-up of this therapy, and other biologics, during the current and future emergencies.

The purpose of this investigation was to describe monoclonal antibody infusion site implementation and requirements during the COVID-19 pandemic using data from 3 sites in the United States, supported by the Office of the Assistant Secretary for Preparedness and Response (ASPR). A set of standard metrics was utilized to evaluate site infusion process staffing model, resources, strengths, and challenges. Diagrams of the monoclonal antibody infusion process components and infusion site physical environment illustrate various therapy implementation layouts. The descriptive metrics analysis informs the implementation of a monoclonal antibody infusion site for the COVID-19 pandemic response efforts and for future use to tackle emerging infectious disease threats. This is a critical window during the pandemic in the United States to examine the implementation of monoclonal antibody infusion sites for outpatients as the response is currently marked by recent therapy EUAs and the steadily growing mass distribution of COVID-19 vaccines.

### Infusion Site Process Assessment

Data were collected from 3 medical centers in the United States, El Centro Regional Medical Center (El Centro, CA), TMC HealthCare (Tucson, AZ), and Sunrise Hospital and Medical Center (Las Vegas, NV) between January and February 2021. These sites recently implemented monoclonal antibody infusions during the pandemic to treat individuals with mild and moderate COVID-19 using EUA criteria and by collaborating with ASPR's National Disaster Medical System (NDMS) Disaster Medical Assistance Teams (DMATs). All 3 medical sites then transitioned to maintaining their own monoclonal antibody infusion sites without ASPR support and incorporated monoclonal antibody infusion into their COVID-19 pandemic response workflows. This investigation was concerned with describing the infusion site process workflows after the DMATs departed and the medical systems transitioned their processes to ensure sustainability during the

COVID-19 pandemic. These sites were selected due to their early adoption of monoclonal antibody delivery while under pandemic stress as COVID-19 "hotspots." The 3 sites also delivered care to diverse and underserved patient populations, and exhibited different process approaches, infrastructures, and physical locations that can inform monoclonal antibody infusion process scale-up across the United States. Two of the sites were temporary tent-based infusion sites and 1 site was a converted former primary care clinic. This clinical support activity was conducted as part of the ASPR public health response to the COVID-19 pandemic and at the request of the host institutions. Under the US Department of Health and Human Services, Office of Health Research Protection guidelines, it was judged a non-research COVID-19 response activity. The Johns Hopkins University Applied Physics Laboratory (JHU/APL) Environmental Health Services Board and all 3 medical sites also deemed this work non-human subjects research exempt from institution review board approval.

### Data Collection and Analysis


Data were collected through 3 mechanisms to inform the monoclonal antibody infusion process assessment, model, and recommendations: (1) key informant interviews, (2) on-site observations, and (3) infusion records. A process assessment framework informed the 7 key metrics on which data were collected to ensure standard data collection at each site (SI Figure 1): logistics, timing, staffing, physical environment, resources, monitoring and resilience, and engagement (SI Table 2). The 7 framework metrics describe critical quantitative and qualitative characteristics of the infusion process to inform the assessment and propose future recommendations.

Semi-structured key informant interviews were conducted at each site using an interview guide to collect data on infusion process assessment metrics to ensure standard data collection. Interviews were conducted with the medical center's Chief Medical Officer, infusion site logistics lead, infection control lead, director of pharmacy, and infusion site staff. Each of the 3 different medical centers' monoclonal antibody infusion sites was visited by the study team to observe and map the infusion process workflow. Each step in the infusion process was timed for multiple patients, and the staff, resources, and information needed for the step were recorded. The on-site observations also facilitated validating data from the key informant interviews.

A descriptive analysis of the monoclonal antibody infusion process was conducted to examine the timing, staffing needs, resources, and information flow of each component of the process. The process was examined from patient engagement through the infusion appointment and discharge from the infusion site. The physical environment of each infusion site was also mapped to analyze resource and implementation needs for this new therapy option. Data on each process metric from the process assessment framework were synthesized and compiled for each site.

### Infusion Site Workflow and Metrics

A descriptive analysis of 3 medical center monoclonal antibody infusion sites was conducted using a process assessment to inform recommendations to strengthen infusion site implementation during current pandemic response efforts. This investigation evaluated the process of monoclonal antibody infusion and staffing equipment, physical space, and resource requirements during the COVID-19 pandemic. A general monoclonal antibody infusion



**Figure 1.** General monoclonal antibody infusion site process workflow examining the network of physical environments, patients, information, calls, staff, and resources, informed by the workflows and assessments of each data collection site.

site workflow process (Figure 1) was developed to integrate the data from the 3 data collection sites. It is important to note that there was not a single standard monoclonal antibody infusion site process workflow. Each site exhibited common process components, staffing models, and resources, yet adapted the system to address local policies, patient populations, and medical center characteristics. An effective monoclonal antibody infusion site optimized the volume of infused patients and minimized patient appointment time and stress on the underlying medical system.

The sites exhibited 2 major medical center mechanisms of implementing a monoclonal antibody infusion site: (1) an outpatient infusion clinic model, and (2) an emergency department (ED) medication visit model (Table 1). Site 1 employed a model tied to ED operations, while Sites 2 and 3 operated as outpatient infusion sites co-located with a medical center. The infusion sites also presented 2 appointment types: 24/7 walk-up and scheduled appointments during business hours. The 3 sites started infusions at different times: first Site 1 started on December 30, 2020, and Sites 2 and 3 initiated infusions the same week, respectively, on January 7 and 8, 2021. Site 1 completed 397 infusions since starting the site with an average rate of 7 infusions per day. Site 2 recorded the highest number of infusions with 824 patients infused, amounting to a rate of approximately 16 infusions per day. Last, Site 3 completed 402 infusions with a rate of 8 patients infused per day. The average rate of patient infusions per day from the field sites was 10 patients per day.

Generally, the process components were initiated by a prospective patient testing positive for SARS-CoV-2, and with scheduling-based infusion sites, patients having first to obtain a provider referral for monoclonal antibody treatment with confirmation that they meet the EUA robust criteria, and timely local SARS-CoV-2 test result turnaround was critical to effective monoclonal antibody implementation, as the current EUA requires the infusion to occur within 10 days of symptom onset in patients with a documented positive COVID-19 viral test result. Areas with SARS-CoV-2 testing turnaround close to 1 week delayed patient referral and created monoclonal antibody uptake obstacles. Infusion site appointments had 3 major components. The first component was a pre-infusion

intake process to confirm patient eligibility, collect vitals, obtain patient consent, and insert an IV. The next component was the monoclonal antibody infusion process, which ranged from 16–60 minutes depending upon the specific therapy available and size of infusion bags. This time was EUA-dependent and this process must remain flexible to changes in infusion requirements, as the guidelines changed from 60 to 16 minutes during the study period. The last component was the EUA-specified 60-minute patient observation period of each patient to monitor for any adverse events.

Three process components contributed the most to patient visit time variability: (1) scheduling appointments, (2) pre-infusion patient intake, and (3) monoclonal antibody coordination with the medical center pharmacy. These 3 process components also created stresses on already constrained staffing resources. A critical barrier of the infusion process at each of the 3 sites was the pharmacy’s preparation of the monoclonal antibody and coordination with the infusion site on therapy doses and timing. Scheduling-based infusion site pharmacies were equipped with data to enable pre-preparation of monoclonal antibody doses in batches before patients arrive. The 3 infusion sites emphasized that coordination with the pharmacy is difficult due to physical proximity and the need to conserve any prepared doses. Monoclonal antibody infusion process workflows were strongly shaped by EUA requirements regarding drug preparation, storage, timing, and delivery.

### Infusion Site Staffing

Similar to the infusion process components, the infusion site staffing metrics varied between sites. The different staffing models relied on the same underlying requirements to ensure monoclonal antibody referral, prescription, preparation, and administration (Table 2). Staffing models differed due to state policies and the different underlying staffing structures of the 3 medical centers. Each staffing model consisted of an advanced practice provider (APP) or physician, a nursing team, and a pharmacy team. The infusion site operations relied heavily on the nursing team, and the more effective infusion process workflows separated the nursing team into

**Table 1.** Monoclonal antibody infusion process logistics and timing metrics from the 3 National Disaster Medical System-supported infusion sites and related strengths and challenges to inform implementation

Logistics and timing metrics	Site 1	Site 2	Site 3	Implementation considerations	
				Strengths	Challenges
<b>Infusion site type</b>	Walk-up tent infusion site	Appointment-based outpatient infusion site	Appointment-based tent infusion site		
<b>Process type</b>	Emergency medical visit	Outpatient infusion procedure	Outpatient infusion procedure		
<b>Infusion site start date</b>	Dec 30, 2020	Jan 7, 2021	Jan 8, 2021		
<b>Total patients infused during study period (Start-Feb 26 2021)</b>	397	824	402	Walk-up sites were beneficial in communities with low health care. system engagement	Walk-up sites exhibited longer wait times for on-demand pharmacy preparation of the monoclonal antibody.
<b>Average rate (patients/day)</b>	7	16	8	Appointment-based sites facilitated batch preparation of monoclonal antibody infusion doses, shortening the overall time of the appointment.	Batch preparation of monoclonal antibodies resulted in unused doses for walk-up systems.
<b>Most significant logistics barriers</b>	Confirming SARS-CoV-2 patient positivity criteria	Coordination with pharmacy for monoclonal antibody preparation	Coordination with pharmacy for monoclonal antibody preparation	30-minute staggering between patient group arrivals improved patient flow due to 15- to 30-minute intake process.	Walk-up site had large variability in timing due to confirming the patient's SARS-CoV-2 positivity upon arrival.
	Coordination with pharmacy for monoclonal antibody preparation	Staffing needs for scheduling process	Staffing needs for scheduling process		
<b>Hours of operation</b>	24 hours/day	Monday-Friday	Monday-Friday		
	7 days a week	9:00 am-5:00 pm	9:00 am-5:00 pm		

2 distinct task areas: patient pre-infusion intake tasks and the infusion-related tasks. The consistent recommendation from the infusion sites for the minimal staffing needs estimated 2 registered nurses (RNs) are needed for every 10 infusion patients. Informed by initial implementation experience, sites recommended developing a process workflow split into 2 staffing components with 1 RN completing pre-infusion and intake processes such as patient initial vitals, data collection, and consent. All sites also recommended integrating paramedics, to start IVs and monitor patients, into the staffing model to alleviate stress on constrained medical center nursing staff. One site leveraged a local medical volunteer organization to support staffing the infusion site during the ongoing pandemic to reduce stress on the medical center's pandemic response staffing. Each of the 3 sites also strongly recommended initiating a multidisciplinary staffing meeting between the medical center's leadership, pharmacy, infection control, ED, nursing, information technology, and security to coordinate the implementation process and medical center staffing allocation. These representatives were not needed for the day-to-day operations of the monoclonal antibody infusion site, but their expertise and support were for developing the initial workflow and staffing models at the 3 sites.

### Physical Environment and Resources

The different external and internal physical environments exhibited by the 3 monoclonal antibody infusion sites were influenced by infection control, resource transport, staffing, and emergency response plan considerations (SI Figures 2–3). Monoclonal antibody recipients are all laboratory-confirmed SARS-CoV-2-positive

patients and likely infectious; consequently, it was critical to separate the infusion site from other medical center operations with uninfected individuals. Two of the sites created temporary tent-based infusion sites next to their ED to maintain a separate physical space and HVAC system for infection control purposes but remain near emergency services for potential adverse events and the pharmacy for monoclonal antibody preparations. One site converted a former primary care clinic located a short distance away from the main medical center into a monoclonal antibody infusion site. This building was only being used by monoclonal antibody patients and the therapy was transferred by a driving courier from the pharmacy in the main medical center campus to the site.

The sites differed in the total number of patients who could be infused at one point in time. While the indoor site allocated 6 rooms for infusion, the 2 tent sites had 10 and 30 infusion chairs (Figure 2). Medical and technological infusion site resources were needed to perform the infusion process, record patient data, and ensure an infection-controlled environment. The resources did not vary greatly between the 3 infusion sites; however, some sites improved the overall monoclonal antibody infusion process by using a mobile, miniature refrigeration unit to store batches of the monoclonal antibody, and scanners to rapidly send prescription and paperwork (Table 3). The temporary tent sites required more infrastructure resources such as electricity sources, power strips, lights, HVAC systems, and generators to remain self-sufficient while adjacent to the medical center. At the current stage in the pandemic, the 3 infusion sites did not report any supply chain barriers related to the physical environment and infusion-related resources.

**Table 2.** Monoclonal antibody infusion process staffing metrics from the 3 National Disaster Medical System-supported infusion sites and strengths and challenges related to staffing and implementation decision-making

Staffing metrics	Infusion site 1	Infusion site 2	Infusion site 3	Implementation considerations	
				Strengths	Challenges
<b>Staffing model</b>	1-3 Registered Nurses (RNs): staff infusion site while also staffing Emergency Department (ED) overflow  1 Physician or Advanced Practice Provider (APP): based in the ED, but oversees referrals and prescriptions  1-2 Pharmacists: prepare the monoclonal antibody and transfer to tent	3-4 RNs:  1 Nurse Practitioner (NP):  1 Pharmacy Technician:  1 Courier: prepared monoclonal antibody from pharmacy to infusion site  1 Scheduler: multiple types of infusions  1 Front Desk Staff Member	2-3 RNs  1 Medically-Credentialed Volunteer:  1 Physician: on-call hospitalist used to oversee referrals and prescriptions  1-2 Pharmacists  1 scheduler (dedicated to infusion site)  1 intake and tent entrance coordinator	Recommended staffing model for monoclonal antibody infusion sites consists of 2 RNs for every 10 infusion patients/chairs.  Staffing models were strengthened by delegating tasks between the 2 RNs with 1 RN dedicated to the pre-infusion/intake process (vitals, registration, consent, etc.) and the other RN dedicated to IV insertion, infusion start, and observation process.  Medically accredited volunteers or paramedics in the community may serve as critical staffing resources for future sites.  Infusion site scheduler or arrival coordinator staffing facilitated shorter total appointment times.  Infusion process is not heavily physician staffing dependent.	Therapy implementation during an ongoing pandemic created large staffing barriers and staff were relocated based upon dynamic medical left needs.  Difficult to dedicate pharmacy staff only to monoclonal antibody preparation.  Staff time and resources are spent on the physical transfer of the monoclonal antibody therapy from the pharmacy to the infusion site.  Scheduling, requests and outreach can encompass large amounts of staff time and resources.  Staffing plans require flexibility as EUA changes also change staff needs, training, and protocols.
<b>Full-time staff</b>	0	5-6	5-6		
<b>Support staff</b>	3-6	4	2-3		
<b>Total staff</b>	3-6	9-10	7-9 (1 volunteer)		


**Resilience, Monitoring, and Engagement**

Sustaining infusion sites through the pandemic required process resilience, monitoring, and engagement (Table 4). Two major barriers that affected process resilience were monoclonal antibody infusion-related adverse events and disruptions to the infusion schedule. The 3 sites had comprehensive plans and resources in place to address a potential adverse event, including the presence of a crash cart at the infusion site, availability of oxygen, patient transport equipment, and medications to treat allergic reactions. The temporary tent sites were also placed adjacent to the ED of the medical centers to ensure close proximity to emergency services if needed. This was a challenge for the off-site physical environment of Site 2 as emergency services would need to be called in the event of an adverse reaction requiring further medical assistance. Disturbances to the schedule were not a potential challenge for Site 1 as it was walk-in based including referrals of ED patients. Sites 2 and 3 emphasized the importance of quickly refrigerating or relabeling an unused monoclonal antibody dose due to patients not arriving for their appointments. This proved to be difficult for sites on Fridays as they were closed on the weekends, and the preservative-free monoclonal antibody drug products must be infused within 24 hours

of preparation. Infusion process monitoring and evaluation varied greatly from site to site: 1 site did not conduct any real-time analysis and other sites implemented dashboards to monitor progress such as average patients per day, tracking adverse events, and patient appointment time estimates. A large barrier to monoclonal antibody infusion site implementation during the COVID-19 pandemic was engagement with patients and providers for education, outreach, and referrals.

**Discussion**

In these 3 ASPR-supported monoclonal antibody infusion sites, our primary finding was that existing processes do not need to be reinvented to implement a successful infusion site during public health emergencies, as the therapy lends itself well to integration into existing outpatient infusion processes and ED/Urgent Care medical visits. The sites implemented various personnel, equipment, and resource modifications to successfully provide monoclonal antibody therapies in communities with large burdens of COVID-19. The general structures of the 3 monoclonal antibody process workflows described here are similar and have consistent



**Figure 2.** Monoclonal antibody infusion site physical environment schematics of Sites 1–3, indicating resources, site type, and layout.

major compartmental steps. Process variations were introduced to address state and local requirements on staffing, prescription orders, and to maintain medical center integration with other COVID-19 response workflows. As the COVID-19 pandemic and EUs evolve, infusion site implementation and maintenance must remain adaptable to changes in therapeutic administration, clinical criteria, requirements, resources, and site needs.

Although a successful monoclonal antibody infusion site can be implemented with minimal staffing needs from the underlying health care system, the physical environment, resources, and work require planning and systems integration to ensure effectiveness, robust infection control, and safety. Medical volunteers or local paramedics can aid in staffing needs and also reduce the burden on the health care system during an emergency. The major strengths of these diverse sites derived from strong community and medical provider engagement on monoclonal antibodies, resilience to process disruptions, and optimized workflows of separating pre-infusion tasking and infusion-related activities between 2 nursing teams. The 3 sites demonstrated successful implementation during a pandemic through strong leadership and staff, collaboration with the NDMS, and flexibility to test and evaluate infusion process workflows. Common barriers and challenges

across the sites included coordinating the preparation of the monoclonal antibody in the pharmacy, as it was not prepared at bedside. However, it is important to note that the EUA allows for the therapy to be prepared at bedside and this preparation mechanism may be more effective at particular types of sites, such as nursing homes, and at-home infusions. Infusion sites that scheduled patients were better able to address this barrier by batch preparing infusion bags and storing them in a refrigerator. Scheduling monoclonal antibody infusion appointments was time- and staff-intensive; however, scheduling enabled more efficient workflows and monoclonal antibody preparation.

Confirming patient test positivity and scheduling individuals within 10 days of their symptom onset were other barriers to optimal monoclonal antibody infusions. Rigorous and timely testing and result communication was a necessary foundation for infusion site success due to the requirement for evidence of a positive test result. Future EUA changes and additional authorizations may address some of the logistical challenges and barriers in infusion site implementation such as reducing infusion times, changing storage and preparation requirements, and expanding patient criteria. Demand for this therapy has not yet been maximized in many communities, and the sites' process workflows can

**Table 3.** Monoclonal antibody infusion process physical environment and resource metrics from the 3 National Disaster Medical System-supported infusion sites and related strengths and challenges

Physical environment & resource metrics	Site 1	Site 2	Site 3	Implementation considerations	
				Strengths	Challenges
<b>Physical environment type</b>	Temporary tents with heating, venting, and air condition (HVAC), electricity, generator, and outdoor mobile restroom	Offsite indoor infusion site	Temporary tent with HVAC, electricity, generator, and outdoor mobile restroom and handwashing station	<p>Temporary tents can lend themselves to easier infection control measures.</p> <p>Temporary tents may allow for closer proximity to emergency services.</p> <p>Indoor infusion sites can be more climate resilient and may have pre-existing resources such as electricity and furniture.</p>	<p>Temporary tents are difficult to implement in inclement weather and are less sustainable for the site long-term.</p> <p>Temporary tent may need services such as electricity, security, wireless internet, generator, and bathroom.</p> <p>Temporary tent rent can be an additional cost if not provided by other entity.</p> <p>Indoor site must have separate entrance, exit, bathroom, and HVAC system from other medical services treating SARS-CoV-2-negative patients.</p> <p>Adjacent, outdoor location to ED removed a significant amount of parking required by increased patient demand at medical lefts.</p>
<b>Monoclonal antibody type(s) infused</b>	Bamlanivimab and REGN-COV2	Bamlanivimab	Bamlanivimab	Easier to allocate and share common resources, such as infusion towers, when in a tent layout.	Tent sites require technological and furniture resources and may require resource storage during off hours.
<b>Medical resources</b>	Intravenous (IV) supplies	IV supplies	IV supplies	Bamlanivimab recently EUA approved reduced infusion times to as little as 16 minutes.	REGN-COV2 can take approximately 10-15 minutes longer to prepare due to vials and packaging.
	Infusion towers/dials	Infusion towers	Infusion towers/dials	Refrigeration capacity at infusion site can allow for unused preparations to be stored for 24-36 hours for future use, depending on specific therapy.	Products are both preservative-free and require immediate use after preparation unless refrigerated.
	Infusion chairs	Infusion chairs	Infusion chairs	Phone capabilities allow for communication with the medical left, emergency services, and other stakeholders.	Medical lefts needed to ensure open supply chains for required medical resources.
	Hospital beds	PPE	PPE	Integrating the infusion site technology with the electronic health record system and electronic communications supported more effective processes.	Infusion sites must be incorporated into biohazard waste medical left plans.
	Personal protective equipment (PPE)	Disinfectant	Disinfectant		
	Disinfectant	Crash cart	Blanket warmers		
	Crash cart	Emergency oxygen	Crash cart		
	Emergency oxygen	Sharps container	Emergency oxygen		
	Sharps container	Biohazard waste disposal	Mini refrigerator (therapy storage)		
	Biohazard waste disposal		Sharps container		
			Biohazard waste disposal		

(Continued)



Table 3. (Continued)

Physical environment & resource metrics	Site 1	Site 2	Site 3	Implementation considerations	
				Strengths	Challenges
<b>Technologic resources</b>	Vitals monitors	Vitals monitors	Vitals monitors		
	Computer to interface with electronic health record	Computer to interface with electronic health record	Computer to interface with electronic health record		
	Fax machine	Infusion site specific phone line	Fax machine to interface with pharmacy		
	Lights		Infusion site specific phone line		
	Power cords		Lights		
	Electricity generator		Power cords		
	HVAC system		Electricity generator		
			HVAC system		
			Security cameras and system		

Table 4. Monoclonal antibody infusion process resilience, monitoring, and engagement metrics from the 3 National Disaster Medical System-supported infusion sites and related strengths and challenges

Resilience, monitoring, & engagement	Site 1	Site 2	Site 3	Implementation considerations	
				Strengths	Challenges
<b>Potential adverse events protocol</b>	Crash-cart located within the tent	Crash-cart located within the tent	Crash-cart located within the tent		
	Site located adjacent to Emergency Department (ED) to address potential adverse events	Offsite of main medical campus, must call 911 for adverse events or related-emergencies	Site located adjacent to ED to address potential adverse events		
<b>Schedule disruption impacts</b>	Lacked pre-established schedule	Doses from scheduled patients who do not arrive were stored in refrigerator for next infusion appointment block within 24 hours	Doses from scheduled patients who do not arrive are stored in refrigerator for next infusion appointment block within 24 hours	Strong engagements with the local community members, providers, and other medical sites built trust and increased therapeutic demand	Difficult to engage and build trust with particular patient and vulnerable communities due to misinformation and disinformation on the COVID-19 pandemic
<b>Monitoring &amp; evaluation of infusion site</b>	No formal monitoring and evaluation tools	Utilized dashboard and electronic health records to monitor and evaluate progress and adjust process	Uses whiteboard and electronic health records to monitor, evaluate, and adjust infusion process and schedule	Utilizing an infusion dashboard and daily data metrics supported productive monitoring and evaluation	Pandemic strain and fatigue served as barriers to engaging providers
<b>Patient engagement</b>	Social media engagement such as Facebook Live	Newspaper and online media	Newspaper and online media	Infusion site proximity to ED optimized rapid care for adverse events	Barrier to stronger patient and community engagement was the delay in monoclonal antibody effectiveness data in outpatient populations
	Local billboards and newspaper articles	Provider referral system	News media interviews Provider referral system	Dose repurposing or dose storage plan critical to address schedule and logistical disruptions	
<b>Provider engagement</b>	Paper-based referral forms sent to provider offices	Provider and urgent care sites via email, fax, and phone	Provider and urgent care sites via email, fax, and phone	Infusion site processes integrated into the pre-existing medical center pandemic response ecosystem	

**Table 5.** Monoclonal antibody infusion therapy and process recommendations for the COVID-19 pandemic and future emerging public health threats

Monoclonal antibody recommendation	Description
<b>Incorporate monoclonal antibodies into pandemic preparedness and response and existing health systems as an early intervention</b>	<p>Monoclonal antibodies can:</p> <ul style="list-style-type: none"> <li>Be manufactured rapidly after neutralizing antibody identification</li> <li>Provide immediate immunologic support when other medical counter measures (MCMs) are under development or require time to achieve full effectiveness such as vaccines</li> <li>Serve as prophylaxis for individuals at high risk for infection</li> <li>Adapt to many forms of deployment during a public health emergency</li> <li>Integrate into existing health system processes such as existing outpatient infusion processes and ED/Urgent Care med visits</li> </ul>
<b>Strengthen process workflow and environment flexibility during public health emergency</b>	<ul style="list-style-type: none"> <li>Adjust monoclonal antibody administration process to policy changes</li> <li>Critical to monitor and evaluate process workflow to optimize and remain flexible to public health emergency conditions</li> <li>Adapt monoclonal antibody administration environment to infection control, weather, drug, and staffing changes</li> </ul>
<b>Adapt staffing models to minimize burden, and maximize targeted skills</b>	<ul style="list-style-type: none"> <li>Establish workflow with minimal staffing needs</li> <li>Balance staffing needs with other emergency response activities</li> <li>Integrate non-traditional health care workers such as medical volunteers and paramedics</li> </ul>
<b>Infusion site location expansion and innovative administration</b>	<ul style="list-style-type: none"> <li><b>Community-based sites:</b> multiple medical centers partner to implement a monoclonal antibody infusion site, share resources and staffing, and minimize individual burden</li> <li><b>Rapid testing adjacent sites:</b> co-locate monoclonal antibody site with rapid testing capabilities to refer and immediately treat patients</li> <li><b>Car-based infusion or injection:</b> alleviate the physical environment by delivering monoclonal antibodies and observing patients in cars</li> <li><b>Home administration:</b> administer monoclonal antibodies in patients' homes</li> <li><b>Nursing homes:</b> administer monoclonal antibodies in nursing homes or long-term care facilities</li> </ul>
<b>Ensure strong engagement and equity</b>	<ul style="list-style-type: none"> <li>Engage with local communities to dispel misinformation and disinformation regarding treatments</li> <li>Empower communities and providers with the knowledge of new therapeutic options and impact data</li> <li>Ensure monoclonal antibody allocation equity by directing information to populations that are vulnerable, most in need, and likely to meet eligibility criteria</li> </ul>
<b>Improved therapy formulations and delivery mechanisms</b>	<ul style="list-style-type: none"> <li>Expand and improve routes of drug administration for therapies, especially rapid methods such as subcutaneous, intramuscular, and microneedle transdermal administration</li> <li>Strengthen temperature stability and minimize drug product preparation requirements</li> </ul>
<b>Standard data collection and effectiveness study integration for outpatients</b>	<ul style="list-style-type: none"> <li>Establish data collection standards for early adopters of monoclonal antibody infusion to permit rapid assessment and large-scale evaluation</li> <li>Pair monoclonal antibody distribution with data collection network to better understand the therapeutic impact during EUA periods</li> </ul>
<b>Sustainable use and public health integration through other disease targets</b>	<ul style="list-style-type: none"> <li>Promote monoclonal antibodies in emerging infectious disease preparedness and response toolkit</li> <li>Build upon the therapeutics momentum from the pandemic</li> <li>Continue innovative monoclonal antibody research and study delivery mechanisms and emergency implementation techniques</li> <li>Partner with organizations researching the application of monoclonal antibodies for other disease targets and public health threats</li> </ul>

accommodate more patients than their average numbers. Community and provider engagement is critical for any new public health measure, but even more so during a pandemic, as all 3 sites reported challenges addressing misinformation and disinformation on COVID-19 treatments and control in their local communities.

The limitations of this descriptive analysis are rooted in its small sample size of 3 sites and limited geographic scope. However, this study has been uniquely conducted during the pandemic to inform ongoing public health action and infusion site implementation during this emergency. These therapies are not yet widely available internationally, and lessons learned now in the United States may

be generalizable to other settings implementing monoclonal antibodies for an emerging infectious disease.

### Recommendations for Current and Future Use

The monoclonal antibody infusion site process description and assessment has informed general recommendations for the current implementation and future use of these therapies to tackle public health emergencies (Table 5). For current use, this monoclonal antibody infusion site process assessment has also supported the development of a data-informed decision support tool called “The mAbs Calculator” hosted for free public use on the ASPR Public Health Emergency website.<sup>14</sup> This calculator provides infusion metrics, recommendations, and data visualizations for monoclonal antibody infusion sites to plan and adapt their staffing, resources, and outputs based upon capacity and workflow inputs.<sup>15</sup> Infusion process workflow and environment adaptability are critical as infusion times, requirements, and staffing change in emergencies. A primary recommendation is to build workflows that can be sustainably maintained in existing pandemic response ecosystems. Optimal staffing models require the minimal number of individuals with the appropriate targeted skills. Medical volunteers, paramedics, and other medical emergency support staff can be leveraged from local services to reduce the burden on the health system.

In public health emergencies, it is important to innovatively expand potential monoclonal antibody administration sites beyond traditional settings. A future outbreak or pandemic could be ignited by a more transmissible pathogen, in which it would be prudent to further minimize staff and patient interactions. One potential solution is patient infusion or injection of a monoclonal antibody therapy with observation in patients’ vehicles, decreasing interactions in a physical environment, space, and indoor infection control systems. This intervention may not be suitable for all settings and vulnerable populations, but it can reduce the strain on physical environments and decrease potential transmission events between patients and health care workers. Further integration of monoclonal antibody delivery into communities could occur by co-locating infusion sites with rapid testing sites so that patients notified of positivity and meeting eligibility criteria could easily access treatment. Infusions and injections may also be administered in the home,<sup>16</sup> removing the need for a physical environment, but potentially increasing the staffing needs and time. As novel treatments arise, such as monoclonal antibodies, strong engagement with the public and equitable distribution of such therapeutics to vulnerable populations is critical.<sup>17</sup> Currently, monoclonal antibodies are delivered via intravenous infusion and subcutaneous administration and research may soon enable intramuscular delivery.<sup>3,18,19</sup> Expanding and improving drug administration routes, especially more rapid methods such as subcutaneous, intramuscular, and microneedle transdermal administration, can support more rapid and less intensive therapy deployment. There is evidence that current monoclonal antibody therapies may show reduced neutralization and potential effectiveness against novel SARS-CoV-2 virus variants to which the drugs were not optimized.<sup>20</sup> However, a strength of monoclonal antibodies is rooted in their adaptability and rapid production. Monoclonal antibody therapies can act as a platform biologic that can be updated as emerging infectious diseases evolve and evade targeting.

Measuring the effectiveness of new therapies, especially in outpatient populations, during a public health emergency, is difficult because resources are focused on saving lives. Establishing site data

collection standards to rapidly assess effectiveness and pairing these with the early distribution of new therapies during an emergency, such as monoclonal antibodies, would improve large-scale evaluation. Implementation lessons learned can be translated for the next pandemic. Innovative research, delivery mechanisms, and implementation techniques for monoclonal antibodies must be further studied and optimized, and this can be accomplished through the lens of other pathogens and public health threats.

The emerging infectious disease preparedness and response toolkit is growing to incorporate monoclonal antibodies, and building upon the therapeutics momentum in the current pandemic is important for the next pandemic.

**Supplementary material.** To view supplementary material for this article, please visit <https://doi.org/10.1017/dmp.2022.15>

**Acknowledgments.** The authors acknowledge the significant efforts of the members of the Disaster Medical Assistance Teams (DMATs) who coordinated the monoclonal antibody infusion site setup, initiation, and integration with the collaborating medical centers. The authors would also like to thank the incredible infusion site leadership, implementation, and clinical staff at El Centro Regional Medical Center (El Centro, CA), TMC HealthCare (Tucson, AZ), and Sunrise Hospital and Medical Center (Las Vegas, NV), who provided extensive time and support for this study.

**Funding statement.** This study was supported by the US Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response (ASPR) through HHS/ASPR contract #: 75A50121C00003.

**Conflict(s) of interest.** None of the authors received any payments or influence from a third-party source for the work presented, and none reports any potential conflict of interest.

### References

1. Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. *JAMA*. 2020;324:131-132. doi: [10.1001/jama.2020.10245](https://doi.org/10.1001/jama.2020.10245)
2. Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*. 2020;584:115-119. doi: [10.1038/s41586-020-2380-z](https://doi.org/10.1038/s41586-020-2380-z)
3. COVID-19 Treatment Guidelines, Anti-SARS-CoV-2 Monoclonal Antibodies. National Institutes of Health (NIH). Published 2021. Accessed April 1, 2021. <https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/>
4. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. *N Engl J Med*. 2020;384:229-237. doi: [10.1056/NEJMoa202984](https://doi.org/10.1056/NEJMoa202984)
5. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. *N Engl J Med*. 2020;384:238-251. doi: [10.1056/NEJMoa2035002](https://doi.org/10.1056/NEJMoa2035002)
6. Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. *JAMA*. 2021;325:632-644. doi: [10.1001/jama.2021.0202](https://doi.org/10.1001/jama.2021.0202)
7. Rainwater-Lovett K, Redd JT, Stewart MA, et al. Real-world effect of monoclonal antibody treatment in COVID-19 patients in a diverse population in the United States. *Open Forum Infect Dis*. 2021;8:ofab398. doi: [10.1093/ofid/ofab398](https://doi.org/10.1093/ofid/ofab398)
8. Bariola JR, McCreary EK, Wadas RJ, et al. Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with severe acute respiratory syndrome coronavirus 2 infection. *Open Forum Infect Dis*. 2021;8(7):ofab254. doi: [10.1093/ofid/ofab254](https://doi.org/10.1093/ofid/ofab254)

9. **Webb BJ, Buckel W, Vento T, et al.** Real-world effectiveness and tolerability of monoclonal antibody therapy for ambulatory patients with early COVID-19. *Open Forum Infect Dis.* 2021;8(7):ofab331. Published 2021 Jun 23. doi: [10.1093/ofid/ofab331](https://doi.org/10.1093/ofid/ofab331)
10. **Rizk, J. G, Forthal DN, Kalantar-Zadeh K, et al.** Expanded access programs, compassionate drug use, and emergency use authorizations during the COVID-19 pandemic. *Drug Discov Today.* 2020. doi: [10.1016/j.drudis.2020.11.025](https://doi.org/10.1016/j.drudis.2020.11.025)
11. **Donnenberg VS.** AAMC discusses monoclonal antibody therapeutics for SARS-CoV-2 infection. *J Clin Pharmacol.* 2021;61:280-281. doi: [10.1002/jcph.1820](https://doi.org/10.1002/jcph.1820)
12. **Cohen MS.** Monoclonal antibodies to disrupt progression of early COVID-19 infection. *N Engl J Med.* 2021;384:289-291. doi: [10.1056/NEJMe2034495](https://doi.org/10.1056/NEJMe2034495)
13. **Sempowski GD, Saunders KO, Acharya P, et al.** Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19. *Cell.* 2020;181:1458-1463. doi: [10.1016/j.cell.2020.05.041](https://doi.org/10.1016/j.cell.2020.05.041)
14. **The mAbs Calculator.** US Department of Health & Human Services (HHS). Published June 22, 2021. Accessed November 17, 2021. <https://www.phe.gov/emergency/mAbs-calculator/Pages/default.aspx>
15. **Caglayan C, Thornhill J, Stewart MA, et al.** Staffing and capacity planning for SARS-CoV-2 monoclonal antibody infusion facilities: a performance estimation calculator based on discrete-event simulations. *Front Public Health.* 2022(2415). doi: [10.3389/fpubh.2021.770039](https://doi.org/10.3389/fpubh.2021.770039)
16. **Malani AN, LaVasseur B, Fair J et al.** Administration of monoclonal antibody for COVID-19 in patient homes. *JAMA Netw Open.* 2021;4:e2129388–e2129388. doi: [10.1001/jamanetworkopen.2021.29388](https://doi.org/10.1001/jamanetworkopen.2021.29388)
17. **Bollyky TJ, Gostin LO, Hamburg MA.** The equitable distribution of COVID-19 therapeutics and vaccines. *JAMA.* 2020;323:2462-2463. doi: [10.1001/jama.2020.6641](https://doi.org/10.1001/jama.2020.6641)
18. **Lanini S, Milleri S, Andreano E, et al.** A single intramuscular injection of monoclonal antibody MAD0004J08 induces in healthy adults SARS-CoV-2 neutralising antibody titres exceeding those induced by infection and vaccination. *medRxiv.* 2021. doi: [10.1101/2021.08.03.21261441](https://doi.org/10.1101/2021.08.03.21261441)
19. **Jung JH, Jin SG.** Microneedle for transdermal drug delivery: current trends and fabrication. *J Pharm Investig.* 2021;51:503-517. doi: [10.1007/s40005-021-00512-4](https://doi.org/10.1007/s40005-021-00512-4)
20. **Hu J, Peng P, Wang K, et al.** Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. *Cell Mol Immunol.* 2021;18:1061-1063. doi: [10.1038/s41423-021-00648-1](https://doi.org/10.1038/s41423-021-00648-1)